Skip to content

Omeros OMER Contract Royalty Asset Current

Contract Royalty Asset Current at other companies

Ceva logo
CevaCEVA
$9.16M+8.3%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$12.15M
Abercrombie & Fitch logo
Abercrombie & FitchANF
$34.31M+3.8%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$50M0.0%
GHC
Graham HoldingsGHC
$2.7M0.0%
Ouster logo
OusterOUST
$1.01M

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$765.73M+313%
P/S8.5×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept omer:ContractRoyaltyAssetCurrent.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's contract royalty asset current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's contract royalty asset current?
Omeros (OMER) reported contract royalty asset current of $25.48M in Q1 2026.
How has Omeros's contract royalty asset current changed year-over-year?
Omeros's contract royalty asset current decreased by 12.8% year-over-year, from $29.23M to $25.48M.
What is the long-term trend for Omeros's contract royalty asset current?
Over 4 years (2021 to 2025), Omeros's contract royalty asset current has grown at a -13.0% compound annual growth rate (CAGR), from $44.32M to $25.35M.
What does contract royalty asset current mean?
This represents the current portion of intangible assets derived from contractual royalty rights expected to be realized within one year. It reflects the present value of future royalty income streams recognized as assets on the balance sheet. Investors monitor this to assess short-term cash flow expectations from licensed intellectual property.